Consistent with our observations, the report showed that the mutations related to CH (i.e., TET2 or DNMT3A) were detected in both the neoplastic T-cell and myeloid compartments in 15 out of 22 AITL patients (68%), and associated with second myeloid neoplasm development after the diagnosis of AITL in 4 cases. The gene discussed is TET2; the disease is myeloid neoplasm.